Development and Validation of the Modified Version of VascuQol Scale in Patients With Lower Extremity Peripheral Arterial Disease.

Launched by RENJI HOSPITAL · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to improve how we understand and assess the impact of lower extremity peripheral arterial disease (PAD) on patients' lives. Specifically, researchers are testing a modified version of a tool called the VascuQol Scale, which helps evaluate the physical and emotional effects of this condition. The goal is to see if this new version can effectively capture how PAD affects patients’ daily lives, allowing for better care and support.

To be eligible for the study, participants need to be between 18 and 90 years old and must have a diagnosis of lower extremity PAD. They should also be willing to attend follow-up evaluations and provide written consent to participate. However, individuals who are pregnant, involved in other clinical studies, or have serious health issues that could affect their quality of life are not eligible. Those who join the study can expect to complete assessments that will help researchers gather important information about how this condition affects them, ultimately aiming to improve the care provided to patients with PAD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female aged 18-90
• • 2. The patient is diagnosed with lower extremity peripheral arterial disease
• • 3. The patient is willing to comply with specified follow-up evaluations at the specified times
• • 4. The patient understands the nature of the procedure and provides written informed consent before enrolment in the study
• • 5. Before enrolment, the guidewire has crossed the target lesion
• • 6. No restrictions on Rutherford grading, TASC grading, GLASS grading
• Exclusion Criteria:
• • 1. Pregnant women or Female patients with potential childbearing
• • 2. The patient is currently participating in another investigational drug or device study that has not reached the primary endpoint.
• • 3. Patients unwilling or refusing to sign informed consent
• • 4. Patients with other diseases that may seriously affect the quality of life, such as tumors, severe liver disease, cardiac insufficiency, etc., or those with a life expectancy of less than 2 years